Another German biopharmaceutical company, CureVac specializes in therapies based on mRNA. Specifically, CureVac features a proprietary RNA platform that may “enable the body to make its own prophylactic and therapeutic drugs,” per its website. While an intriguing market idea based on the forward implications of mRNA-based technologies, CVAC presents significant risks, even compared to other clinical-stage biotech stocks.
Since the start of this year, CVAC suffered a catastrophic loss of almost 77%. Even worse, nearer-term momentum implies the pain has yet to abate, with CVAC incurring a 21% loss in the trailing month.
On the financial spectrum as well, CureVac could use some help. In Q2 2022, the company posted revenue of $21.3 million, down 21% from the year-ago quarter. Additionally, CureVac posted a net loss of $60.9 million in the most recent quarter.
However, the development and distribution of mRNA COVID vaccines should theoretically bolster underlying biotech stocks in the long run due to proven viability. Therefore, risk-tolerant investors may want to consider CVAC.
Will CureVac Stock Go Up?
Turning to Wall Street, CVAC stock has a Moderate Buy consensus rating based on two Buys assigned in the past three months. The average CVAC price target is $37, implying 369.50% upside potential.
A global late-stage clinical mRNA medicines and vaccines company, Arcturus Therapeutics represents a bold bet on the future of advanced medical technologies. As with CureVac, Arcturus features proprietary technologies along with key partnerships with the broader aim to deliver innovative therapeutic solutions.
Currently, Arcturus is developing a COVID-19 vaccine specifically geared toward the omicron variant. As well, the biotech firm seeks solutions for long-term diseases and conditions. For example, Arcturus is collaborating with the Cystic Fibrosis Foundation to develop mRNA-based medicine to treat cystic fibrosis.
Nevertheless, prospective buyers of ARCT must be prepared for a potentially choppy ride, even stacked against higher-risk biotech stocks to buy. Shares are down roughly 58% year-to-date, reflecting tremendous volatility. However, Arcturus posted revenue of $27 million in Q2 2022, significantly outpacing the $2 million posted in the year-ago quarter.
Should investors have the patience and long-term outlook, ARCT could be intriguing as RNA-related biotech stocks rise on the success of the COVID-19 vaccine.
Is ARCT a Good Stock to Buy?
Turning to Wall Street, ARCT stock has a Hold consensus rating based on three Buys, three Holds, and two Sells assigned in the past three months. The average ARCT price target is $40.86, implying 175.71% upside potential.
Market Data 
Markets 
AI
